EU approves Aquipta for prophylaxis of migraine – AbbVie
AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval… read more.
AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval… read more.
Pelvic pain in women with endometriosis is attributed to neuroinflammation. Researchers investigated biochemical mediators of endometriosis-associated pelvic pain to provide a foundation to identify new drugs to improve… read more.
Over the last 10 years, there has been a shift to fewer codeine prescriptions and an increase in prescriptions for stronger opioids, such as hydrocodone, hydromorphone and oxycodone… read more.
Starting a patient-controlled epidural anesthesia (PCEA) infusion while the patient is still in the operating room (OR) — rather than in the recovery room after the procedure —… read more.
In the first randomized trial to study the efficacy of opioid pain relievers for the treatment of acute lower back and neck pain for up to one year,… read more.
An estimated 3 million patients visit emergency departments each year with acute chest pain and mildly elevated troponin levels. High levels of troponin, a protein, occur when the… read more.
Opioid pain-relieving medicines are not more effective than a placebo in relieving acute back and neck pain and may even cause harm, according to a world-first trial led… read more.
Increasing access to prescription opioid painkillers may reduce opioid overdose deaths in the United States, according to a Rutgers study. “When access to prescription opioids is heavily restricted,… read more.
Trevena, Inc. announced new topline Olinvyk data from the ARTEMIS study. The ARTEMIS study was an electronic medical records (EMR) based assessment focused on clinical and health resource… read more.
Researchers report that treatment with bempedoic acid in high-risk primary prevention patients who cannot tolerate recommended doses of statins reduces major adverse cardiovascular events. The findings were published… read more.
Braeburn announces that the FDA has approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder… read more.
Analysis of over 30 years of data has shown the number of cases of low back pain is growing, with modelling suggesting by 2050, 843 million people will… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.